Global Avian Influenza Vaccine Market

Avian Influenza Vaccine Market Size, Share, Growth Analysis, By Strain(H5, H7, and H9), By Application(Chicken, Turkey, and Goose & Duck), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2886 | Region: Global | Published Date: May, 2024
Pages: 215 | Tables: 63 | Figures: 70

Avian Influenza Vaccine Market Dynamics

Drivers

Rise in Rate of Diseases

  • Avian influenza can be defined as a disease caused by avian influenza virus type-A. This virus is commonly found in waterfowl and can infect domestic chickens and other bird species. Based on viral surface proteins, subtypes of influenza type A viruses can be classified into neuraminidase (NA) and hemagglutinin (HA). Based on their molecular characteristics and ability to cause disease and death in chicken avian influenza viruses are classified as highly pathogenic and low pathogenicity but both in poultry, high prevalence is reported. Nonpathogenic bird flu viruses show no signs of illness. Only mild diseases such as egg decline and wildflies show it. However, infection with the highly pathogenic influenza virus is associated with high mortality.

Growing Incidence of Poultry Mortality

  • Increasing incidence of disease, especially in developing regions, is a major cause of mortality in more than 90% of poultry farms. High demand for poultry vaccines, ongoing research to develop effective vaccines, and rising incidence of infectious diseases contribute to the global influenza vaccines market but these vaccines rapid deterioration at room temperature in two hours makes it unsuitable for transport to remote villages. Furthermore, according to the U.S. According to the Department of Agriculture (U.S. DA), currently available vaccines do not meet efficacy requirements and therefore, should not be used to treat avian influenza outbreaks.

Restraints

Viral Mutational Challenges

  • The rapid mutation rate of avian influenza virus presents a challenge to maintain vaccine coverage. There are ongoing research opportunities to understand the dynamics of the virus and to improve the quality of vaccines accordingly.

Global Distribution Challenges

  • Global avian influenza vaccination, especially in poultry-rich areas, remains a challenge. There are also opportunities for collaboration in the distribution system to overcome access barriers.

Health Approach

  • Development opportunities are based on a single approach to health that considers the links between human, animal and environmental health. This holistic approach is necessary to manage the complexity of avian influenza.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Avian Influenza Vaccine Market size was valued at USD 140.0 Billion in 2022 and is poised to grow from USD 145.88 Billion in 2023 to USD 202.74 Billion by 2031, growing at a CAGR of 4.2% in the forecast period (2024-2031).

The competitive environment of the Avian Influenza Vaccine Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'Boehringer Ingelheim International GmbH (Germany)', 'Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China)', 'Ceva (US)', 'Yebio Bioengineering Co., Ltd (China)', 'Zoetis (US)', 'FATRO S.P.A. (Italy)', 'CAVAC (South Korea)', 'Tianjin Ringpu Bio-Technology Co., Ltd (China)', 'PT Japfa Comfeed Indonesia Tbk (Indonesia)', 'Chengdu Tech-bank Biological Products Co., Ltd (China)', 'Merck Animal Health (US)', 'Medion (Indonesia)', 'Avimex Animal Health (Mexico)', 'JOVAC (Jordan)', 'QYH BIOTECH COMPANY LIMITED (China)'

Avian influenza can be defined as a disease caused by avian influenza virus type-A. This virus is commonly found in waterfowl and can infect domestic chickens and other bird species. Based on viral surface proteins, subtypes of influenza type A viruses can be classified into neuraminidase (NA) and hemagglutinin (HA). Based on their molecular characteristics and ability to cause disease and death in chicken avian influenza viruses are classified as highly pathogenic and low pathogenicity but both in poultry, high prevalence is reported. Nonpathogenic bird flu viruses show no signs of illness. Only mild diseases such as egg decline and wildflies show it. However, infection with the highly pathogenic influenza virus is associated with high mortality.

Along with Israel, China, India and South Korea have the highest number of bird flu viruses in Asia-Pacific. This is followed by rapid supply chain improvements and a growing R&D infrastructure through supportive government policies.

The avian influenza vaccine market is dominated by Asia Pacific. This can be attributed to increased poultry production and increasing outbreaks of bird flu in the region. China produced 13,900 thousand metric tons of poultry meat in 2022, according to a recent Foreign Agricultural Service/USDA report, it is estimated that the U.S. will exhibit significant market growth due to growing meat and poultry industry, increasing animal health expenditure.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Avian Influenza Vaccine Market

Report ID: SQMIG35A2886

$5,300
BUY NOW GET FREE SAMPLE